↓ Skip to main content

Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia

Overview of attention for article published in Gut Pathogens, February 2016
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
4 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Increased dosage of infliximab is a potential cause of Pneumocystis carinii pneumonia
Published in
Gut Pathogens, February 2016
DOI 10.1186/s13099-016-0086-4
Pubmed ID
Authors

Takuya Iwama, Aki Sakatani, Mikihiro Fujiya, Kazuyuki Tanaka, Shugo Fujibayashi, Yoshiki Nomura, Nobuhiro Ueno, Shin Kashima, Takuma Gotoh, Junpei Sasajima, Kentaro Moriichi, Katsuya Ikuta

Abstract

Pneumocystis carinii pneumonia occasionally appears in immunodeficient patients. While several reports have shown that Pneumocystis carinii pneumonia occurred in the early phase of starting infliximab treatment in patients with Crohn's disease (CD), the present case suggests for the first time that an increased dosage of infliximab may also lead to pneumonia. A 51-year-old male had been taking 5 mg of infliximab for the treatment of CD for 10 years with no adverse events. Beginning in September 2013, the dose of infliximab had to be increased to 10 mg/kg because his status worsened. Thereafter, he complained of a fever and cough, and a CT scan revealed ground-glass opacities in the lower lobes of the bilateral lung with a crazy-paving pattern. Bronchoscopy detected swelling of the tracheal mucosa with obvious dilations of the vessels. A polymerase chain reaction using a bronchoalveolar lavage fluid sample detected specific sequences for Pneumocystis jirovecii; thus he was diagnosed with Pneumocystis carinii (jirovecii) pneumonia. After discontinuing infliximab and starting antibiotic treatment, his symptoms and CT findings were dramatically improved. The administration of an increased dosage of infliximab can cause Pneumocystis carinii pneumonia in CD patients.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 17%
Other 1 8%
Student > Doctoral Student 1 8%
Lecturer 1 8%
Student > Ph. D. Student 1 8%
Other 1 8%
Unknown 5 42%
Readers by discipline Count As %
Medicine and Dentistry 4 33%
Immunology and Microbiology 1 8%
Veterinary Science and Veterinary Medicine 1 8%
Unknown 6 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 February 2016.
All research outputs
#17,783,561
of 22,842,950 outputs
Outputs from Gut Pathogens
#332
of 522 outputs
Outputs of similar age
#270,535
of 397,125 outputs
Outputs of similar age from Gut Pathogens
#12
of 13 outputs
Altmetric has tracked 22,842,950 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 522 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.8. This one is in the 26th percentile – i.e., 26% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 397,125 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.